WQ5 Stock Chart & Stats
€0.02
€0.00(0.00%)
At close: 4:00 PM EDT
€0.02
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.04
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€16.23M
Enterprise Value€11.62M
Total Cash (Recent Filing)€111.79K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Sep 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding566,409,800
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-14.33
Price to Sales (P/S)0.00
P/FCF Ratio-5.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetThe absence of financial debt reduces refinancing exposure and avoids interest obligations that could further pressure a loss-making business. This gives management more flexibility when allocating limited capital to research and development, although the broader balance sheet remains constrained by negative equity.
Improving Free Cash Flow TrendImprovement in free cash flow during 2025 indicates some progress in cash usage relative to the prior year. If sustained, better cash discipline could extend the company’s operating runway and reduce funding pressure, even though current cash generation remains insufficient to support the business independently.
Longevity Gene-Therapy FocusA focused research strategy around gene therapy, age-related disease, and longevity biology gives the company exposure to a potentially durable scientific and healthcare theme. Concentrating resources on defined ageing pathways may support specialized expertise and clearer program priorities as development advances.
Bears Say
Pre-Revenue Loss-Making ModelThe company has not yet demonstrated commercial revenue generation, while continuing operating losses show that its programs have not reached a self-sustaining stage. This leaves future financial performance dependent on successful development, partnering, or commercialization rather than an established revenue base.
Negative Shareholders’ EquityThe move into increasingly negative shareholders’ equity indicates that accumulated losses have overwhelmed the company’s capital base. This weakens balance-sheet resilience, limits financial flexibility, and makes future operations more dependent on raising additional capital or securing external support.
Persistent Cash BurnMulti-year negative operating and free cash flow shows that the business cannot currently fund its activities from internally generated cash. Continued research spending without self-funding capacity creates an enduring need for external financing, which can constrain strategy and increase dilution or funding risk.
Genflow Biosciences Plc News
WQ5 FAQ
What was Genflow Biosciences Plc’s price range in the past 12 months?
Genflow Biosciences Plc lowest stock price was <€0.01 and its highest was €0.04 in the past 12 months.
What is Genflow Biosciences Plc’s market cap?
Genflow Biosciences Plc’s market cap is €16.23M.
When is Genflow Biosciences Plc’s upcoming earnings report date?
Genflow Biosciences Plc’s upcoming earnings report date is Sep 25, 2026 which is in 16 days.
How were Genflow Biosciences Plc’s earnings last quarter?
Genflow Biosciences Plc released its earnings results on Apr 30, 2026. The company reported -€0.001 earnings per share for the quarter.
Is Genflow Biosciences Plc overvalued?
According to Wall Street analysts Genflow Biosciences Plc’s price is currently Overvalued.
Does Genflow Biosciences Plc pay dividends?
Genflow Biosciences Plc does not currently pay dividends.
What is Genflow Biosciences Plc’s EPS estimate?
Genflow Biosciences Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genflow Biosciences Plc have?
Genflow Biosciences Plc has 566,409,800 shares outstanding.
What happened to Genflow Biosciences Plc’s price movement after its last earnings report?
Genflow Biosciences Plc reported an EPS of -€0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Genflow Biosciences Plc?
Currently, no hedge funds are holding shares in DE:WQ5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genflow Biosciences Plc
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducing the incidence of age-related diseases. Its lead drug candidate is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-1003, a topical delivery of SIRT6 to the fibroblasts in the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005, which addresses mitochondrial dysfunction observed in sarcopenia for muscle health and combat sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. The company has collaborative research agreements with Revatis SA and EXO Biologics for therapy medicinal products. Genflow Biosciences plc was founded in 2020 and is headquartered in London, the United Kingdom.
Technical Analysis
Oxford BioDynamics
―
Physiomics
―
Fusion Antibodies Plc
―
4basebio UK Societas
―
Aptamer Group Plc
―